Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Combination Treatment of Invasive Fungal Infections

Combination Treatment of Invasive Fungal Infections Combination Treatment of Invasive Fungal Infections Pranab K. Mukherjee 1 , Daniel J. Sheehan 2 , Christopher A. Hitchcock 3 and Mahmoud A. Ghannoum 1 , * 1 Center for Medical Mycology, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio 2 Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York 3 Exploratory Development, Pfizer Global Research & Development, Sandwich Laboratories, Sandwich, United Kingdom SUMMARY The persistence of high morbidity and mortality from systemic fungal infections despite the availability of novel antifungals points to the need for effective treatment strategies. Treatment of invasive fungal infections is often hampered by drug toxicity, tolerability, and specificity issues, and added complications often arise due to the lack of diagnostic tests and to treatment complexities. Combination therapy has been suggested as a possible approach to improve treatment outcome. In this article, we undertake a historical review of studies of combination therapy and also focus on recent studies involving newly approved antifungal agents. The limitations surrounding antifungal combinations include nonuniform interpretation criteria, inability to predict the likelihood of clinical success, strain variability, and variations in pharmacodynamic/pharmacokinetic properties of antifungals used in combination. The issue of antagonism between polyenes and azoles is beginning to be addressed, but data regarding other drug combinations are not adequate for us to draw definite conclusions. However, recent data have identified potentially useful combinations. Standardization of assay methods and adoption of common interpretive criteria are essential to avoid discrepancies between different in vitro studies. Larger clinical trials are needed to assess whether combination therapy improves survival and treatment outcome in the most seriously debilitated patients afflicted with life-threatening fungal infections. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Microbiology Reviews American Society For Microbiology

Combination Treatment of Invasive Fungal Infections

Combination Treatment of Invasive Fungal Infections

Clinical Microbiology Reviews , Volume 18 (1): 163 – Jan 1, 2005

Abstract

Combination Treatment of Invasive Fungal Infections Pranab K. Mukherjee 1 , Daniel J. Sheehan 2 , Christopher A. Hitchcock 3 and Mahmoud A. Ghannoum 1 , * 1 Center for Medical Mycology, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio 2 Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York 3 Exploratory Development, Pfizer Global Research & Development, Sandwich Laboratories, Sandwich, United Kingdom SUMMARY The persistence of high morbidity and mortality from systemic fungal infections despite the availability of novel antifungals points to the need for effective treatment strategies. Treatment of invasive fungal infections is often hampered by drug toxicity, tolerability, and specificity issues, and added complications often arise due to the lack of diagnostic tests and to treatment complexities. Combination therapy has been suggested as a possible approach to improve treatment outcome. In this article, we undertake a historical review of studies of combination therapy and also focus on recent studies involving newly approved antifungal agents. The limitations surrounding antifungal combinations include nonuniform interpretation criteria, inability to predict the likelihood of clinical success, strain variability, and variations in pharmacodynamic/pharmacokinetic properties of antifungals used in combination. The issue of antagonism between polyenes and azoles is beginning to be addressed, but data regarding other drug combinations are not adequate for us to draw definite conclusions. However, recent data have identified potentially useful combinations. Standardization of assay methods and adoption of common interpretive criteria are essential to avoid discrepancies between different in vitro studies. Larger clinical trials are needed to assess whether combination therapy improves survival and treatment outcome in the most seriously debilitated patients afflicted with life-threatening fungal infections.

Loading next page...
 
/lp/american-society-for-microbiology/combination-treatment-of-invasive-fungal-infections-MzxXD8OT7w

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Society For Microbiology
Copyright
Copyright © 2005 by the American society for Microbiology.
ISSN
0893-8512
eISSN
1098-6618
DOI
10.1128/CMR.18.1.163-194.2005
pmid
15653825
Publisher site
See Article on Publisher Site

Abstract

Combination Treatment of Invasive Fungal Infections Pranab K. Mukherjee 1 , Daniel J. Sheehan 2 , Christopher A. Hitchcock 3 and Mahmoud A. Ghannoum 1 , * 1 Center for Medical Mycology, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio 2 Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York 3 Exploratory Development, Pfizer Global Research & Development, Sandwich Laboratories, Sandwich, United Kingdom SUMMARY The persistence of high morbidity and mortality from systemic fungal infections despite the availability of novel antifungals points to the need for effective treatment strategies. Treatment of invasive fungal infections is often hampered by drug toxicity, tolerability, and specificity issues, and added complications often arise due to the lack of diagnostic tests and to treatment complexities. Combination therapy has been suggested as a possible approach to improve treatment outcome. In this article, we undertake a historical review of studies of combination therapy and also focus on recent studies involving newly approved antifungal agents. The limitations surrounding antifungal combinations include nonuniform interpretation criteria, inability to predict the likelihood of clinical success, strain variability, and variations in pharmacodynamic/pharmacokinetic properties of antifungals used in combination. The issue of antagonism between polyenes and azoles is beginning to be addressed, but data regarding other drug combinations are not adequate for us to draw definite conclusions. However, recent data have identified potentially useful combinations. Standardization of assay methods and adoption of common interpretive criteria are essential to avoid discrepancies between different in vitro studies. Larger clinical trials are needed to assess whether combination therapy improves survival and treatment outcome in the most seriously debilitated patients afflicted with life-threatening fungal infections.

Journal

Clinical Microbiology ReviewsAmerican Society For Microbiology

Published: Jan 1, 2005

There are no references for this article.